Last reviewed · How we verify
PQed Typhoid Conjugate Vaccine
PQed Typhoid Conjugate Vaccine stimulates immune response against Salmonella typhi by presenting conjugated polysaccharide antigens to the adaptive immune system.
PQed Typhoid Conjugate Vaccine stimulates immune response against Salmonella typhi by presenting conjugated polysaccharide antigens to the adaptive immune system. Used for Prevention of typhoid fever caused by Salmonella typhi.
At a glance
| Generic name | PQed Typhoid Conjugate Vaccine |
|---|---|
| Sponsor | PT Bio Farma |
| Drug class | Conjugate vaccine |
| Target | Salmonella typhi polysaccharide antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This is a conjugate vaccine that links typhoid polysaccharide antigens to a protein carrier, enhancing T-cell dependent B-cell responses and generating both antibody and cellular immunity. The conjugation strategy improves immunogenicity compared to unconjugated polysaccharide vaccines, particularly in younger populations, and provides protection against typhoid fever caused by Salmonella typhi.
Approved indications
- Prevention of typhoid fever caused by Salmonella typhi
Common side effects
- Injection site pain or erythema
- Fever
- Headache
- Myalgia
Key clinical trials
- Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PQed Typhoid Conjugate Vaccine CI brief — competitive landscape report
- PQed Typhoid Conjugate Vaccine updates RSS · CI watch RSS
- PT Bio Farma portfolio CI